Alto Neuroscience, Inc. 8K

Alto Neuroscience reported Q2 2026 results, expanded its ALTO-207 depression program with a planned Phase 3 monotherapy trial, advanced multiple Phase 2b studies, and strengthened its balance sheet with a $100 million equity financing expected to fund operations through 2030.

Alto Neuroscience, Inc. reported its financial results for the quarter ended June 30, 2026 and provided an extensive business update, highlighted by expansion of its ALTO-207 development program to include a planned Phase 3 monotherapy trial in treatment-resistant depression (TRD) alongside an ongoing potentially registrational Phase 2b adjunctive trial, publication of supportive independent clinical data in Nature Medicine, continued progress of its ALTO-300 and ALTO-100 Phase 2b programs, and completion in July 2026 of an underwritten registered direct equity offering raising approximately $100 million, resulting in pro forma cash of about $338 million expected to fund operations through 2030 despite ongoing net losses driven by increased R&D spending.

Filing Facts

CIK

1999480

Ticker

ANRO

Form

8K

Source Type

fda

Accession

0001999480-26-000022

Alert Tier

7